Avalo Therapeutics Inc
NASDAQ:AVTX 12:37:59 AM EDT
| Market Cap (Intraday) | 15.81M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $14.03 |
| 50-Day MA | $9.06 |
| 200-Day MA | $21.30 |
Avalo Therapeutics Inc Stock, NASDAQ:AVTX
540 Gaither Road, Suite 400, Rockville, Maryland 20850
United States of America
Phone: +1.410.522.8707
Number of Employees: 19
Description
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.